Abstract
Multiple chemotherapy regimens are available for the treatment of metastatic pancreas cancer (mPCA). Choice of regimen is based on the patient’s performance status and toxicity profile of the regimen. The objective of this study was to analyze the costs of first-line regimens to further aid in decision-making and develop a platform upon which to assess value. We calculated the monthly cost for individual standard regimens (gemcitabine, gemcitabine/nab-paclitaxel, gemcitabine/erlotinib and FOLFIRINOX) and the overall treatment cost for a course of therapy based on the median progression-free survival achieved in published studies. In addition to cost of drugs, we included administration costs and costs of toxicities (including growth factor support, blood product transfusion and hospitalization for toxicities). Costs for administration and management of adverse events were based on Medicare reimbursement rates for hospital and physician services. Drug costs were based on Medicare average sale prices (all 2014 US$). The monthly costs for gemcitabine, FOLFIRINOX, gemcitabine/erlotinib and gemcitabine/nab-paclitaxel were $1363, $7234, $8007 and $12,221, respectively. The overall treatment costs for a course of the same regimens based on median PFS were $5043, $46,298, $51,004 and $67,216, respectively. The choice of chemotherapy regimen for mPCA should be based on tolerability and efficacy of the regimen individualized to patient’s performance status. Healthcare systems have finite resources; thus, there is increasing emphasis on metrics to define value in health care when outcomes of therapy are similar or produce marked differences in value. These data provide useful financial information to incorporate into the decision-making process.
Similar content being viewed by others
References
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29.
Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403–13.
Mariotto AB, Yabroff KR, Shao Y, et al. Projections of the cost of cancer care in the united states: 2010-2020. J Natl Cancer Inst. 2011;103:117–28.
Conroy T, Desseigne F, Ychou M, et al. Folfirinox versus gemcitabine for metastatic pancreatic cancer. New Engl J Med. 2011;364:1817–25.
Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–703.
Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase iii trial of the national cancer institute of canada clinical trials group. J Clin Oncol. 2007;25:1960–6.
Schnipper LE, Davidson NE, Wollins DS, et al. American society of clinical oncology statement: a conceptual framework to assess the value of cancer treatment options. J Clin Oncol. 2015;33(23):2563–77.
Excellence NIfHaC (2014) The cost of nab-paclitaxel is not justified by its limited benefit, says nice in draft guidance.
Krishna K, Wei L, Daniel HA, Wu C S-Y, Ciombor KK, Mikhail S, Noonan AM, Goldberg RM, Bekaii-Saab TS (2015) Modified gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer (mpc): a single-institution experience. Presented at 2015 ASCO Gastrointestinal Cancers Symposium, San Francisco, 2015.
Centers for Disease Control Homepage. http://www.cdc.gov/nchs/fastats/.
Goldstein DA, Chen Q, Ayer T, et al. First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a united states-based cost-effectiveness analysis. J Clin Oncol. 2015;33(10):1112–8.
Medicare physician fee schedule. 2013. https://www.cms.gov/apps/physician-fee-schedule/.
Tumeh JW, Moore SG, Shapiro R, et al. (2005) Practical approach for using medicare data to estimate costs for cost-effectiveness analysis.
Okera M, Chan S, Dernede U, et al. A prospective study of chemotherapy-induced febrile neutropenia in the South West London Cancer Network. Interpretation of study results in light of ncag/ncepod findings. Br J Cancer. 2011;104:407–12.
Winkelmayer WC, Weinstein MC, Mittleman MA, et al. Health economic evaluations: the special case of end-stage renal disease treatment. Med Decis Making. 2002;22:417–30.
Lee CP, Chertow GM, Zenios SA. An empiric estimate of the value of life: updating the renal dialysis cost-effectiveness standard. Value Health. 2009;12:80–7.
Aristides M, Lees M, Botwood N, et al. Economic evaluation of gemcitabine in the treatment of pancreatic cancer in the UK. Eur J Health Econ. 2003;4:216–21.
Attard CL, Brown S, Alloul K, et al. Cost-effectiveness of folfirinox for first-line treatment of metastatic pancreatic cancer. Curr Oncol. 2014;21:e41–51.
Tam VC, Ko YJ, Mittmann N, et al. Cost-effectiveness of systemic therapies for metastatic pancreatic cancer. Curr Oncol. 2013;20:e90–106.
Drummond M, Barbieri M, Cook J, et al. Transferability of economic evaluations across jurisdictions: ISPOR good research practices task force report. Value Health. 2009;12:409–18.
Rugo HS, Barry WT, Moreno-Aspitia A, et al. Randomized phase iii trial of paclitaxel once per week compared with nanoparticle albumin-bound nab-paclitaxel once per week or ixabepilone with bevacizumab as first-line chemotherapy for locally recurrent or metastatic breast cancer: Calgb 40502/ncctg n063 h (alliance). J Clin Oncol. 2015;33:2361–9.
Bekaii-Saab T, Noonan AM, Lesinski G, et al. A multi-institutional randomized phase 2 trial of the oncolytic virus reolysin in the first line treatment metastatic adenocarcinoma of the pancreas. Lba19/abstract 8535 esmo annual meeting. European Society of Medical Oncology (ESMO) annual meeting. Madrid. Ann Oncol. 2014;2014:1–41.
Saltz LB. Can money really be no object when cancer care is the subject? J Clin Oncol;2015.
Cherny NI, Sullivan R, Dafni U, et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: The European society for medical oncology magnitude of clinical benefit scale (esmo-mcbs). Ann Oncol 2015.
Ramsey S, Shankaran V. Managing the financial impact of cancer treatment: the role of clinical practice guidelines. JNCCN. 2012;10:1037–42.
Network NCC. Nccn evidence blocks; 2015. http://www.nccn.org/about/news/newsinfo.aspx?NewsID=546.
Acknowledgments
Daniel A. Goldstein was funded with NIH T32 grant: T32CA160040-02.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
Daniel A. Goldstein, Kavya Krishna, Christopher R. Flowersand Anne M Noonan declare no conflicts of interest; Bassel F El-Rayes is a paid advisory board consultant for Genentech and Merrimack; Tanios Bekaii-Saab is a paid consultant for Genentech.
Rights and permissions
About this article
Cite this article
Goldstein, D.A., Krishna, K., Flowers, C.R. et al. Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer. Med Oncol 33, 48 (2016). https://doi.org/10.1007/s12032-016-0762-8
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s12032-016-0762-8